Live Market Updates
Latest Financial News
News Feed
1 articles
Personalized
Live Market Updates
Latest Financial News
positive
1 day agoMedpace forecasts solid Q3 2025 revenue and earnings amid expanding clinical research demand
Medpace Holdings (MEDP) expects Q3 2025 revenue of $641 million and earnings per share of approximately $3.57, supported by robust contract research demand across pharma and biotech clients. For the full year, management projects revenue between $2.42 billion and $2.52 billion with EBITDA ranging from $515 million to $545 million. Growth is driven by new trial awards in oncology and rare diseases and improved client retention. The company emphasized operational discipline and capacity expansion in Asia and Europe. Analysts expect continued margin stability due to automation in data management and enhanced regulatory efficiency.
positive
1 day agoMedpace forecasts solid Q3 2025 revenue and earnings amid expanding clinical research demand
Medpace Holdings (MEDP) expects Q3 2025 revenue of $641 million and earnings per share of approximately $3.57, supported by robust contract research demand across pharma and biotech clients. For the full year, management projects revenue between $2.42 billion and $2.52 billion with EBITDA ranging from $515 million to $545 million. Growth is driven by new trial awards in oncology and rare diseases and improved client retention. The company emphasized operational discipline and capacity expansion in Asia and Europe. Analysts expect continued margin stability due to automation in data management and enhanced regulatory efficiency.
positive
Medpace forecasts solid Q3 2025 revenue and earnings amid expanding clinical research demand
1 day ago
1 min read
93 words
Medpace expects Q3 revenue of $641M and EPS of $3.57, with FY25 revenue guidance of $2.42B–$2.52B driven by strong trial demand in oncology and rare diseases.
Medpace Holdings (MEDP) expects Q3 2025 revenue of $641 million and earnings per share of approximately $3.57, supported by robust contract research demand across pharma and biotech clients. For the full year, management projects revenue between $2.42 billion and $2.52 billion with EBITDA ranging from $515 million to $545 million. Growth is driven by new trial awards in oncology and rare diseases and improved client retention. The company emphasized operational discipline and capacity expansion in Asia and Europe. Analysts expect continued margin stability due to automation in data management and enhanced regulatory efficiency.
Medpace Holdings (MEDP) expects Q3 2025 revenue of $641 million and earnings per share of approximately $3.57, supported by robust contract research demand across pharma and biotech clients. For the full year, management projects revenue between $2.42 billion and $2.52 billion with EBITDA ranging from $515 million to $545 million. Growth is driven by new trial awards in oncology and rare diseases and improved client retention. The company emphasized operational discipline and capacity expansion in Asia and Europe. Analysts expect continued margin stability due to automation in data management and enhanced regulatory efficiency.
Companies:
Medpace Holdings
Tags:
Medpace
clinical research
Medpace
clinical research
earnings
biotech
Source:
Oct 22, 2025 • 17:44 IST